Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of 5-Amino-1MQ and SLU-PP-332 — mechanism, side effects, legal status, and pricing.
5-Amino-1MQ is a small heterocyclic molecule (not a peptide) that acts as a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). It is under preclinical investigation for obesity and non-alcoholic fatty liver disease. It is not FDA-approved and has not completed human clinical trials; it is commonly tracked alongside peptides because grey-market vendors sell it for metabolic protocols.
SLU-PP-332 is a small-molecule (non-peptide) pan-agonist of estrogen-related receptors ERRα/β/γ developed at Saint Louis University. Studied preclinically as an exercise mimetic in rodents, it has no human clinical data and is NOT FDA-approved. Sold only as a grey-market research chemical.
5-Amino-1MQ
SLU-PP-332
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
5-Amino-1MQ
SLU-PP-332
COA corpus from Disclosed Labs — independently tested batches only.
5-Amino-1MQ
80
COAs
99.5%
Avg purity
12
Labs
SLU-PP-332
26
COAs
99.5%
Avg purity
11
Labs
Neelakantan et al. (2018, Biochem Pharmacol, PMID 29155147) reported that 5-Amino-1MQ and related selective, membrane-permeable methylquinolinium NNMT inhibitors reversed high-fat-diet-induced obesity in mice, reducing body weight, white adipose mass, adipocyte size, and plasma cholesterol without changing food intake. A separate NNMT inhibitor program (Kannt et al., 2018, Sci Rep, PMID 29483571, JBSNF-000088) produced similar metabolic effects in rodents. Dimet-Wiley et al. (2022, Sci Rep, PMID 35013352) reported microbiome changes with NNMT inhibition plus low-fat diet in DIO mice, and Babula et al. (2024, Diabetes Obes Metab, PMID 39161060) showed 5A1MQ dose-dependently limited weight and fat gain and reduced NAFLD-like liver pathology in DIO mice. No human clinical trials of 5-Amino-1MQ have been completed or published as of 2026; grey-market oral protocols are not clinically validated.
Key references
Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.
Key references
5-Amino-1MQ and SLU-PP-332 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs